Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipafricept + Paclitaxel/Carboplatin in Recurrent Ovarian Cancer
NCT02092363Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Oct 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipafricept in ovarian cancer, sponsored by OncoMed Pharmaceuticals. Primary endpoint: Safety and tolerability of OMP-54F28 in combination with paclitaxel and carboplatin. Started Jan 2014; status: completed.
02
Drugs
ipafricept
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02092363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092363.